摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate | 1283095-53-3

中文名称
——
中文别名
——
英文名称
tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate
英文别名
t-butyl 2-[(2-chlorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate
tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate化学式
CAS
1283095-53-3
化学式
C25H31ClFNO3S
mdl
——
分子量
480.043
InChiKey
MBDXRMKEKJGJEO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    67
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography
    摘要:
    Positron emission tomography (PET) coupled to an effective radioligand could provide an important tool for understanding possible links between neuropsychiatric disorders and brain NOP (nociceptin/orphanin FQ peptide) receptors. We sought to develop such a PET radioligand. High-affinity NOP ligands were synthesized based on a 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2(2-halobenzyl)-N-alkylpropanamide scaffold and from experimental screens in rats, with ex vivo LC-MS/MS measures, three ligands were identified for labeling with carbon-11 and evaluation with PET in monkey. Each ligand was labeled by C-11-methylation of an N-desmethyl precursor and studied in monkey under baseline and NOP receptor-preblock conditions. The three radioligands, [C-11] (S) 10a-c, gave similar results. Baseline scans showed high entry of radioactivity into the brain to give a distribution reflecting that expected for NOP receptors. Preblock experiments showed high early peak levels of brain radioactivity, which rapidly declined to a Much lower level than seen in baseline scans, thereby indicating a high level of receptor-specific binding in baseline experiments. Overall, [C-11](S)-10c showed the most favorable receptor-specific signal and kinetics and is now selected for evaluation in human subjects.
    DOI:
    10.1021/jm101487v
  • 作为产物:
    参考文献:
    名称:
    Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography
    摘要:
    Positron emission tomography (PET) coupled to an effective radioligand could provide an important tool for understanding possible links between neuropsychiatric disorders and brain NOP (nociceptin/orphanin FQ peptide) receptors. We sought to develop such a PET radioligand. High-affinity NOP ligands were synthesized based on a 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2(2-halobenzyl)-N-alkylpropanamide scaffold and from experimental screens in rats, with ex vivo LC-MS/MS measures, three ligands were identified for labeling with carbon-11 and evaluation with PET in monkey. Each ligand was labeled by C-11-methylation of an N-desmethyl precursor and studied in monkey under baseline and NOP receptor-preblock conditions. The three radioligands, [C-11] (S) 10a-c, gave similar results. Baseline scans showed high entry of radioactivity into the brain to give a distribution reflecting that expected for NOP receptors. Preblock experiments showed high early peak levels of brain radioactivity, which rapidly declined to a Much lower level than seen in baseline scans, thereby indicating a high level of receptor-specific binding in baseline experiments. Overall, [C-11](S)-10c showed the most favorable receptor-specific signal and kinetics and is now selected for evaluation in human subjects.
    DOI:
    10.1021/jm101487v
点击查看最新优质反应信息

文献信息

  • Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor
    作者:Concepción Pedregal、Elizabeth M. Joshi、Miguel A. Toledo、Celia Lafuente、Nuria Diaz、Maria A. Martinez-Grau、Alma Jiménez、Ana Benito、Antonio Navarro、Zhaogen Chen、Daniel R. Mudra、Steven D. Kahl、Karen S. Rash、Michael A. Statnick、Vanessa N. Barth
    DOI:10.1021/jm201629q
    日期:2012.6.14
    understanding of the relationship between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor. Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomography (PET) radioligand suitable to probe the NOP receptor in human clinical studies. A thorough structure–activity relationship (SAR) around
    当前,缺乏足够的工具限制了对神经精神疾病与伤害感受素/孤儿啡FQ(N / OFQ)肽(NOP)受体之间关系的理解。在本文中,我们描述了拮抗剂NOP受体占有率(RO)示踪剂和适合在人类临床研究中探测NOP受体的新型正电子发射断层扫描(PET)放射性配体的发现和发展。高亲和力3-(2'-氟-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3- c ]吡喃] -1-周围的结构-活性关系(SAR)yl)-2-(2-卤代苄基)-N-烷基丙酰胺支架鉴定了一系列亚纳摩尔的高选择性NOP拮抗剂。随后,在大鼠体内通过液相色谱-串联质谱法(LC-MS / MS)对这些未标记的NOP配体进行了体内评估,以确定脑摄取,动力学和特异性结合。(S)-27被确定为合适的未标记临床前RO示踪剂,可准确定量大鼠脑中NOP受体的参与。选择了三种化合物在非人类灵长类动物中作为PET示踪剂进行评估:(-)- 26,(-)- 30和(-)-
  • Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography
    作者:Victor W. Pike、Karen S. Rash、Zhaogen Chen、Concepción Pedregal、Michael A. Statnick、Yasuyuki Kimura、Jinsoo Hong、Sami S. Zoghbi、Masahiro Fujita、Miguel A. Toledo、Nuria Diaz、Susan L. Gackenheimer、Johannes T. Tauscher、Vanessa N. Barth、Robert B. Innis
    DOI:10.1021/jm101487v
    日期:2011.4.28
    Positron emission tomography (PET) coupled to an effective radioligand could provide an important tool for understanding possible links between neuropsychiatric disorders and brain NOP (nociceptin/orphanin FQ peptide) receptors. We sought to develop such a PET radioligand. High-affinity NOP ligands were synthesized based on a 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2(2-halobenzyl)-N-alkylpropanamide scaffold and from experimental screens in rats, with ex vivo LC-MS/MS measures, three ligands were identified for labeling with carbon-11 and evaluation with PET in monkey. Each ligand was labeled by C-11-methylation of an N-desmethyl precursor and studied in monkey under baseline and NOP receptor-preblock conditions. The three radioligands, [C-11] (S) 10a-c, gave similar results. Baseline scans showed high entry of radioactivity into the brain to give a distribution reflecting that expected for NOP receptors. Preblock experiments showed high early peak levels of brain radioactivity, which rapidly declined to a Much lower level than seen in baseline scans, thereby indicating a high level of receptor-specific binding in baseline experiments. Overall, [C-11](S)-10c showed the most favorable receptor-specific signal and kinetics and is now selected for evaluation in human subjects.
查看更多

同类化合物

化合物SEP-363856HYDROCHLORIDE 6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-甲胺 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸乙酯 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸 5,7-二氢-4H-噻吩并[2,3-c]吡喃-3-羧酸 5,7-二氢-4H-噻吩并[2,3-C]吡喃-3-羧酸乙酯 4-(2-羟基乙基)-4-甲基-6,7-二氢-4h-噻吩并[3,2-c]吡喃 4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 4',5'-二氢-螺[哌啶-4,7'-[7H]噻吩并[2,3-c]吡喃]-1-羧酸叔丁酯 2-氯-4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 2-氨基-5,5-二甲基-4,7-二氢-5H-噻吩并[2,3-C]吡喃-3-羧酸叔丁酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-羧酸乙酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-甲腈 2-[[(苯甲酰基氨基)硫代甲酰]氨基]-4,7-二氢-5,5-二甲基-5H-噻吩并[2,3-C]吡喃-3-羧酸 (4-甲基-6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-基)乙酸 (2-羧基噻吩-3-基)乙酸酐 2-(3-hydroxy-2,2-dimethylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide 2-[[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-5-methyl-1H-pyrazole-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-fluoronicotinamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-oxopyrrolidine-3-carboxamide 2-(1-(hydroxymethyl)cyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide tert-butyl 2-(3-(3,4-dimethoxyphenyl)thioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate trans-6-(benzyloxy)-2-carbamoyl-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-carbomethoxy-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-cyano-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-bromo-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran 5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-cyano-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran cis-7-amino-5,6-dihydro-6-hydroxy-5,5-dimethyl-5H-thieno<3,2-b>pyran 2-[3-(3-trifluoromethyl[1,2,4]oxadiazol-5-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4-trifluoromethylthiazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4,5-dimethyloxazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 4,4-dimethyl-6,7-dihydro-4H-thieno[3,2-c]pyran 1,1-(3-dimethylamino-3-phenyl-methylene)-3,4-dihydro-1H-2-oxa-9-thia-fluoren N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine triflate N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine trans-5,6-dihydro-6-hydroxy-2,5,5-trimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran 5-Cyclohexyl-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxylic acid tert-butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-methyl-1H-pyrazole-3-carboxamide 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-5H-thieno[3,2-b]pyran-2-carbonitrile 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-2-(thiazolin-2-yl)-5-thieno[3,2-b]pyran